The ETER701 trial demonstrates that a four-drug regimen, involving the addition of anti-angiogenesis therapy to immuno-chemotherapy, improves survival outcomes for extensive-stage small-cell lung cancer — but is more indeed better when it comes to treating this intractable disease?
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Sen, T. et al. Nat. Rev. Clin. Oncol. 21, 610–627 (2024).
Megyesfalvi, Z. et al. CA Cancer J. Clin. 73, 620–652 (2023).
Cheng, Y. et al. Nat. Med. https://doi.org/10.1038/s41591-024-03132-1 (2024).
Spigel, D. R. et al. J. Clin. Oncol. 29, 2215–2222 (2011).
Tiseo, M. et al. J. Clin. Oncol. 35, 1281–1287 (2017).
Zhang, W. et al. Lung Cancer 173, 43–48 (2022).
Meder, L. et al. Cancer Res. 78, 4270–4281 (2018).
Su, Y. et al. Clin. Cancer Res. 28, 793–809 (2022).
Socinski, M. A. et al. N. Engl. J. Med. 378, 2288–2301 (2018).
Lamberti, G. et al. J. Thorac. Oncol. 18, S168–S169 (2023).
Ohe, Y. et al. J. Clin. Oncol. 42 (suppl.), Abstract 8001 (2024).
Nabet, B. Y. et al. Cancer Cell 42, 429–443.e424 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Li, N., Wang, SY. Navigating treatment combinations in small-cell lung cancer. Nat Med 30, 2731–2732 (2024). https://doi.org/10.1038/s41591-024-03255-5
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-024-03255-5
